Small Study Tests Colchicine for Moderate to Severe COVID-19
For patients with moderate-to-severe COVID-19, colchicine reduces the length of supplemental oxygen therapy and hospitalization.
For patients with moderate-to-severe COVID-19, colchicine reduces the length of supplemental oxygen therapy and hospitalization.
The American College of Rheumatology developed clinical guidance for the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases.
The FDA has issued an Emergency Use Authorization for Lilly’s SARS-CoV-2 neutralizing antibodies bamlanivimab plus etesevimab.
Investigators determined whether ABO and Rh blood groups were associated with risk for SARS-CoV-2 infection and severe COVID-19 illness.
In this episode, we get an insight into the current COVID-19 landscape from a rheumatologist’s perspective.
In this interview, Richard Becker, MD, gives us an insight into COVID-19 vasculitis and its manifestations.
The EUA submission is based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.
During the COVID-19 pandemic period, there have been inequities in accessing telemedicine.
Single-dose vaccine candidate JNJ-78436725 against COVID-19 met primary and key secondary end points.
The mucocutaneous features seen in hospitalized children with MIS-C and how these findings are associated with the onset of systemic symptoms are characterized.